Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
Changes to This Summary (01/31/2019)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added this new section.
Revised text about the patient eligibility requirements and treatment regimens for the open COG-AALL1131 (NCT01406756) trial.
Revised text about the patient eligibility requirements and treatment regimens for the open COG-AALL1131 (NCT01406756) trial.
Added text to state that for patients with B-cell ALL who relapse after allogeneic hematopoietic stem cell transplantation (HSCT) and can be successfully weaned from immune suppression and have no graft-versus-host disease, tisagenlecleucel and other 4-1BB chimeric antigen receptor (CAR) T-cell approaches have resulted in event-free survival rates exceeding 50% at 12 months. Also revised text to state that for patients with T-cell ALL who relapse or for patients with B-cell ALL who are unable to undergo CAR T-cell therapy, a second ablative allogeneic HSCT may be feasible. Also added Kuhlen et al. as reference 121.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No comments:
Post a Comment